Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Prolactinoma
Interventions
DRUG

Cabergoline (Dopamine Agonist)

Cabergoline is available in tablet form, with doses of 0.5 mg per tablet. The standard dosing for hyperprolactinemia typically starts at 0.25 mg to 0.5 mg per week, which can be gradually increased based on the patient's response, with a usual range of 0.25 mg to 2 mg per week. The dose required to achieve the target prolactin levels (pre- defined for each intervention arm) may vary between patients, so a fixed dose is not specified. This allows for individualized treatment based on each patient's response.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Dept. of Endocrinology, Metabolism & Diabetes, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER